Clinical Efficacy and Safety of Pentanedioic Acid Imidazolyl Ethanamide in Patients Aged 3 to 6 years with Influenza and other Acute Respiratory Viral Infections Based on the Results of Double-Blind Randomized Placebo-Controlled Multicenter Study

Study Goals. Assessment of the efficacy and safety of the Pentanedioic Acid Imidazolyl Ethanamide (IPA) in the treatment of influenza and other acute respiratory viral infections (ARVI) in children aged 3–6 years.
Children Characteristics and Study Methods. The randomized double-blind placebo-controlled multicenter clinical study involving 190 patients aged 3–6 years was carried out as follows: 95 patients received IPA at 30 mg/day dose once for 5 days and 95 patients – placebo using the same pattern. The therapy efficacy was assessed by the body temperature, dynamics of the individual symptoms of the disease as per the Severity Scale for the patients with influenza and other acute respiratory viral infections (Scale) and the incidence rate of complications of the acute respiratory viral infections. The primary endpoint is the period of the score reduction on the Scale to 2 points, providing that there is not more than 1 score on the individual subscales with the body temperature normalization from the start of treatment. The safety analysis was carried out using the assessment of the nature and incidence rate of the adverse events.
Results. The IPA use at 30 mg/day dose significantly promotes the achievement of goals for the primary endpoint – the average value in the IPA group is 91.79 h (95% confidence interval – CI from 87.45 to 96.13), in the placebo group – 100.12 h (95% CI from 96.73 to 103.51). In the IPA group, the body temperature returned to normal by 18.56 h faster in average compared with the placebo. The regression of the catarrhal and intoxication symptoms was significantly promoted with the IPA use as follows: by the 3rd day of the therapy, the average score on the Scale was 5.22 points for IPA, and it was statistically significantly lower than that in the placebo group – 6.21 points. The comparative analysis of the incidence rate of adverse events did not reveal the statistically significant differences between IPA and placebo. None of the adverse events recorded was clinically significant, and none caused the cancellation or change in the dosage of the study drug.
Conclusions. IPA broad-spectrum antiviral drug at 30 mg/day dose has demonstrated the high efficacy in the treatment of the acute respiratory viral infections of various etiologies in children aged 3–6 years. The IPA use compared with the placebo causes the significant reduction of the fever period, accelerates the relief of the intoxication and catarrhal symptoms, and decreases the recovery time. The IPA is characterized by high tolerability and high safety, which allows to recommend the drug for the treatment of influenza and ARVI (acute respiratory viral infections) in children from 3 years of age.

1. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year [cited 2018 Apr 10]. Available from: http://www.who.int/ru/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonalflu-each-year].

2. Nazzari E., Torretta S., Pignataro L., Marchisio P., Esposito S. Role of biofilm in children with recurrent upper respiratory tract infections. Eur J Clin Microbiol Infect Dis 2014; 34(3): 421–429. DOI: 10.1007/s10096-014-2261-1 2

3. Russell C.D., Unger S.A., Walton M., Schwarze J. The Human Immune Response to Respiratory Syncytial Virus Infection. Clin Microbiol Rev 2017; 30(2): 481–502. DOI: 10.1128/cmr.00090-16

4. Lindemans C.A., Kimpen J.L.L., Luijk B., Heidema J., Kanters D., van der Ent C.K., Koenderman L. Systemic eosinophil response induced by respiratory syncytial virus. Clin Exp Immunol 2006; 144(3): 409–417. DOI: 10.1111/j.1365-2249.2006.03084.x

5. Kawasaki Y., Hosoya M., Kanno H., Suzuki H. Serum regulated upon activation, normal T cell expressed and presumably secreted concentrations and eosinophils in respiratory syncytial virus infection. Pediatrics Inter 2006; 48(3): 257–260. DOI: 10.1111/j.1442-200x.2006.02199.x

6. Larrañaga C.L., Ampuero S.L., Luchsinger V.F., Carrión F.A., Aguilar N.V., Morales P.R., Avendaño L.F. Impaired Immune Response in Severe Human Lower Tract Respiratory Infection by Respiratory Syncytial Virus. Pediatr Infect Dis J 2009; 28(10): 867–873. DOI: 10.1097/inf.0b013e3181a3ea71

7. Brand H.K., Ferwerda G., Preijers F., de Groot R., Neeleman C., Staal F.J.T., Hermans P.W.M. CD4+ T-cell counts and interleukin-8 and CCL-5 plasma concentrations discriminate disease severity in children with RSV infection. Pediatr Res 2012; 73(2): 187–193. DOI: 10.1038/pr.2012.163

8. Brand H.K., Ahout I.M.L., de Ridder D., van Diepen A., Li Y., Zaalberg M., Staal F.J.T. Olfactomedin 4 Serves as a Marker for Disease Severity in Pediatric Respiratory Syncytial Virus (RSV) Infection. PLOS ONE 2015; 10(7): e0131927. DOI: 10.1371/journal.pone.0131927

9. De Souza A.P.D., de Freitas D.N., Antuntes Fernandes K.E., D’Avila da Cunha M., Antunes Fernandes J.L., Benetti Gassen R., Stein R.T. Respiratory syncytial virus induces phosphorylation of mTOR at ser2448 in CD8 T cells from nasal washes of infected infants. Clin Exp Immunol 2015; 183(2): 248–257. DOI: 10.1111/cei.12720

10. Reed J.L., Welliver T.P., Sims G.P., McKinney L., Velozo L., Avendano L., Welliver R.C. Innate Immune Signals Modulate Antiviral and Polyreactive Antibody Responses during Severe Respiratory Syncytial Virus Infection. J Infect Dis 2009; 199(8): 1128–1138. DOI: 10.1086/597386

11. Habibi M.S., Jozwik A., Makris S., Dunning J., Paras A., DeVincenzo J.P., Chiu C. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med 2015; 191(9): 1040–1049. DOI: 10.1164/rccm.201412-2256oc

12. Matsuno A.K., Gagliardi T.B., Paula F.E., Luna L.K.S., Jesus B.L.S., Stein R.T. et al. Human coronavirus alone or in co-infection with rhinovirus C is a risk factor for severe respiratory disease and admission to the pediatric intensive care unit: A one-year study in Southeast Brazil. PLoS One 2019; 14(6): e0217744. DOI: 10.1371/journal.pone.0217744

13. Soudani N., Caniza M.A., Assaf-Casals A., Shaker R., Lteif M., Su Y., Tang L. et al. Prevalence and characteristics of acute respiratory virus infections in pediatric cancer patients. J Med Virol 2019; 91(7): 1191–1201. DOI: 10.1002/jmv.25432

14. De Corso E., Lucidi D., Cantone E., Ottaviano G., Di Cesare T., Seccia V. et al. Clinical Evidence and Biomarkers Linking Allergy and Acute or Chronic Rhinosinusitis in Children: a Systematic Review. Curr Allergy Asthma Rep 2020; 20(11): 68. DOI: 10.1007/s11882-020-00967-9

15. Jeng M.J., Lee Y.S., Tsao P.C., Yang C.F., Soong W.J. A longitudinal study on early hospitalized airway infections and subsequent childhood asthma. PLoS One 2015; 10(4): e0121906. DOI: 10.1371/journal.pone.0121906

16. Инструкция по медицинскому применению препарата Ингавирин® (ЛСР-006330/08, ЛП-002968, ЛП-006482). [Patient information leaflet of Ingavirin/ (in Russ.)] https://grls.rosminzdrav.ru/GRLS

17. Шульдяков А.А., Ляпина Е.П., Кузнецов В.И., Зрячкин Н.И., Ситников И.Г., Перминова О.А. и др. Новые возможности терапии острых респираторных вирусных инфекций у детей. Вопросы практической педиатрии 2015; 10(5): 21–28. [Shul’dyakov A.A., Lyapina E.P., Kuznetsov V.I., Zryachkin N.I., Sitnikov I.G., Perminova O.A. et al. New possibilities in therapy of acute respiratory viral infections in children. Voprosy Prakticheskoi Pediatrii 2015; 10(5): 21 – 28. (in Russ.)]

18. Геппе Н.А., Теплякова Е.Д., Шульдяков А.А., Ляпина Е.П., Перминова О.А., Мартынова Г.П. и др. Инновации в педиатрии: оптимальный клинический эффект при лечении ОРВИ у детей препаратом комплексного действия. Педиатрия 2016; 95(2): 96–103. [N.A. Geppe N.A., Teplyakova E.D., Shul’dyakov A.A., Lyapina E.P., Perminova O.A., Martynova G.P. et al. Innovations in pediatrics: the optimal clinical effect in acute respiratory viral infections treatment in children with complex action drug. Pediatria 2016; 95(2): 96 – 103. (in Russ.)]

19. Фарбер И.М., Геппе Н.А., Рейхарт Д.В., Небольсин В.Е., Арнаутов В.С., Глобенко А.А. Терапия гриппа и прочих ОРВИ у детей младшего и среднего школьного возраста: влияние препарата Ингавирин® на интоксикационный, лихорадочный и катаральный синдромы. Российский вестник перинатологии и педиатрии 2016; 61(2): 115–120. [Farber I.M., Geppe N.A., Reikhart D.V., Nebolsin V.E., Arnautov V.S., Globenko A.A. Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2016; 61(2):115–120. DOI: 10.21508/1027-4065-2016-61-2-115-120 (in Russ.)]

20. Геппе Н.А., Малахов А.Б., Кондюрина Е.Г. Обоснование выбора противовирусной терапии ОРВИ в педиатрии (метаанализ клинических исследований эффективности имидазолилэтанамида пентандиовой кислоты у детей разных возрастных групп). Вопросы практической педиатрии 2020; 15(3): 106–114. [Geppe N.A. Malakhov, A.B., Kondyurin E.G. Rationale for the choice of ARVI antiviral therapy in pediatrics (meta-analysis of pentanedioic acid imidazolyl ethanamide clinical studies for ARVI treatment in children of different age groups). Voprosy Prakticheskoi Pediatrii 2020; 15(3): 106–114. DOI: 10.20953/1817-7646-2020-3-106-114(in Russ.)]

21. Taylor J.A., Weber W.J., Martin E.T., McCarty R.L., Englund J.A. Development of a symptom scores for clinical studies to identify children with a documented viral upper respiratory tract infection. Pediatr Res 2010; 68(3): 252–257. DOI: 10.1203/PDR.0b013e3181e9f3a0

22. Kim H.H., Lee M.H., Lee J.S. Eosinophil Cationic Protein and Chemokines in Nasopharyngeal Secretions of Infants with Respiratory Syncytial Virus (RSV) Bronchiolitis and Non-RSV Bronchiolitis. J Korean Med Sci 2007; 22(1): 37. DOI: 10.3346/jkms.2007.22.1.37

23. Dimova-Yaneva D., Russell D., Main M., Brooker R.J., Helms P.J. Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis. Clin Exp Allergy 2004; 34(4): 555–558. DOI: 10.1111/j.1365-2222.2004.1918.x

24. Ye Q., Shao W.-X., Shang S.-Q., Pan Y.-X., Shen H.-Q., Chen X.-J. Epidemiological characteristics and immune status of children with Respiratory Syncytial Virus. J Med Virol 2014; 87(2): 323–329. DOI: 10.1002/jmv.24047

25. Mella C., Suarez-Arrabal M.C., Lopez S., Stephens J., Fernandez S., Hall M.W., Mejias A. Innate Immune Dysfunction is Associated with Enhanced Disease Severity In Infants with Severe Respiratory Syncytial Virus Bronchiolitis. J Infect Dis 2012; 207(4): 564–573. DOI: 10.1093/infdis/jis721

26. Diaz P.V., Pinto R.A., Mamani R., Uasapud P.A., Bono M.R., Gaggero A.A., Goecke A. Increased Expression of the Glucocorticoid Receptor in Infants with RSV Bronchiolitis. Pediatrics 2012; 130(4): e804–e811. DOI: 10.1542/peds.2012-0160

27. Hattori S., Shimojo N., Mashimo T., Inoue Y., Ono Y., Kohno Y. et al. Relationship between RANTES polymorphisms and respiratory syncytial virus bronchiolitis in a Japanese infant population. Jpn J Infect Dis 2011; 64(3): 242–245.

28. Chung H.L., Park H.J., Kim S.Y., Kim S.G. Age-related difference in immune responses to respiratory syncytial virus infection in young children. Pediatr Allergy Immunol 2007; 18(2): 94–99. DOI: 10.1111/j.1399-3038.2006.00501.x